KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 121 filers reported holding KALA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $54,000 | -12.9% | 39,416 | +66.8% | 0.00% | -50.0% |
| Q3 2021 | $62,000 | -83.9% | 23,634 | -67.4% | 0.01% | -93.8% |
| Q2 2021 | $384,000 | +308.5% | 72,490 | +421.5% | 0.13% | +330.0% |
| Q1 2021 | $94,000 | -46.0% | 13,900 | -70.5% | 0.03% | -42.3% |
| Q4 2019 | $174,000 | -3.3% | 47,195 | 0.0% | 0.05% | -22.4% |
| Q3 2019 | $180,000 | – | 47,195 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |